Ceftobiprole for Treatment of MRSA Blood Stream Infection: A Case Series

Figures & data

Table 1 Descriptions of the Cases

Year	Age (Gender)	Underlying Condition	Clinical Syndrome	Prior Therapy	Reason for Switch	Duration of Ceftobiprole	Concomitant Abx	ICU	Clinical Outcome*	Microbiological Outcome*	30 Days Mortality
2019	18 Y (M)	Large B cell Lymphoma	CLABSI	Vancomycin 5 days	Combination	24 days	Vancomycin	No	Improved	Cleared	Alive**
2019	79 Y (M)	CHF, Paraplegic	Vertebral osteomyelitis	Vancomycin 4 days	Combination	24 days	Vancomycin	Yes	Improved	Cleared	Alive
2018	17 Y (M)	Burn	SSTI/Burn	Vancomycin 7 days	Concomitant infections	30 days	Other Gram-negative coverage	Yes	Improved	Cleared	Alive
2018	74 Y (M)	Ischemic heart diseases, DM, HTN	Endocarditis	Vancomycin 7 days → Vancomycin +Daptomycin 21 days	Toxicity related to Daptomycin	76 days	No	Yes	Improved	Cleared	Alive**
2019	71 Y (M)	Bedridden, dementia	Diabetic foot osteomyelitis/cellulitis	Vancomycin 7 days → Daptomycin 5 days	Failure of prior therapy	16 days	Vancomycin	Yes	Improved	Cleared	Alive**
2019	55 Y (M)	DM, HTN	Pneumonia	Vancomycin 14 days	Failure of prior therapy	16 days	No	No	Improved	Cleared	Alive

Notes: *At 14 days of starting Ceftobiprole. **Died later after 6, 7, 3 months respectively.

Abbreviations: M, male; ICU, intensive care unit admission; CLABSI, central line-associated bloodstream infection; CHF, congestive heart failure; SSTI, skin and soft tissue infections; DM, diabetes mellitus; HTN, hypertension.